Condition
Stage III Adrenal Cortex Carcinoma
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Terminated1
Withdrawn1
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06006013Phase 2Recruiting
Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer
NCT02720484Phase 2Terminated
Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer
NCT02831179Phase 1Withdrawn
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Showing all 3 trials